drugset / Trial / NCT07257640
IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single-arm clinical study designed to evaluate the efficacy and safety of IL-5 CAR-T cell therapy in the treatment of patients with CD125-positive eosinophilic leukemia.
Timeline
- Start
- 2025-11-30
- Primary completion
- 2028-11-30
- Completion
- 2028-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IL-5 CAR-T cells | Cell therapy | — | Intravenous |